Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Retifanlimab

Review the clinical trials studying retifanlimab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-13 of 13

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Status: Active
Location: 9 locations
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Status: Active
Location: 11 locations
Carmustine Wafers in Combination with Retifanlimab and Standard of Care Radiation with or without Temozolomide for the Treatment of Newly Diagnosed Glioblastoma or Gliosarcoma
Status: Active
Location: 4 locations
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Status: Active
Location: 4 locations
Tretinoin and Retifanlimab in Treating Patients with Recurrent IDH-Mutant Glioma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Retifanlimab with or without Gemcitabine and Docetaxel in Patients with Advanced, Unresectable or Metastatic Soft Tissue Sarcoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Axatilimab in Combination with Retifanlimab and Paclitaxel for the Treatment of Patients with Advanced or Metastatic Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Tafasitamab, Retifanlimab, and Rituximab in Combination with Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Neoantigen-Based Personalized DNA Vaccine and Retifanlimab for the Treatment of Patients with Newly Diagnosed, Unmethylated Glioblastoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Status: Active
Location: See ClinicalTrials.gov
Combination Study of SV-BR-1-GM With Retifanlimab
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov